Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Medical Case Reports
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Computed Tomography | Case report

Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report

Authors: Caroline Y. Chen, Charlene M. Fares, Daniel Sanghoon Shin

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Introduction

Tyrosine kinase inhibitors (TKI) targeting epidermal growth factor receptor (EGFR) are approved for use in metastatic non-small cell lung cancer (NSCLC).

Case presentation

Here we present a case of a African American patient with stage IIIA NSCLC treated with osimertinib in the neoadjuvant setting with concurrent radiation, followed by resection. The patient remains disease-free 4 months after surgery.

Conclusion

This case report suggests that osimertinib may be effective as neoadjuvant therapy in resectable stage III disease. Additionally, we provide a summary of previous case reports and ongoing clinical trials for neoadjuvant EGFR inhibition in stage III NSCLC patients.
Literature
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
2.
Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389:299–311.CrossRef
3.
Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of Stage III non-small cell lung cancer. Chest. 2013;143:e314S-e340S.CrossRef
4.
Ramalingam SS, Yang JCH, Lee CK, et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:841–9.CrossRef
5.
Xiong L, Li R, Sun J, et al. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm Phase II Study. Oncologist. 2019;24:157.CrossRef
6.
Zheng W, Mao W. Preoperative neoadjuvant gefitinib used in the treatment of a nonsmall cell lung cancer patient. Transl Surg. 2017;2:22.CrossRef
7.
Mazzoni F, Petreni P, Perna M, et al. Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences. Tumori. 2018;104(6):NP5-NP9.
8.
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. N Engl J Med. 2017;377:1919–29.CrossRef
9.
Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37:2235–45.CrossRef
10.
Akamatsu H, Harada H, Tokunaga S, et al. A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). Clin Lung Cancer. 2019;20(1):e25–7.CrossRef
11.
Pennell NA, Neal JW, Chaft JE, et al. SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. J Clin Oncol. 2019;37(2):97–104.CrossRef
12.
Herbst RS, Tsuboi M, John T, et al. Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA. ASCO20 Virtual Scientific Program. In: Abstract LBA5. Presented in premeeting press briefing on May 26; 2020.
Metadata
Title
Osimertinib as neoadjuvant therapy in a patient with stage IIIA non-small cell lung cancer: a case report
Authors
Caroline Y. Chen
Charlene M. Fares
Daniel Sanghoon Shin
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-02748-y

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue

Case report

Kawasaki disease presenting after intussusception: a case report

Case report

New Delhi metallo-β-lactamase-1 among Escherichia coli strains isolated from leukemia patients in Iran: two case reports

Correction

Correction to: Recurrent spontaneous abortion related to balanced translocation of chromosomes: two case reports

Case report

Severe sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report

Case report

Trisomy 5p with bilateral congenital diaphragmatic hernia: a case report

Case report

An incidental finding of testicular seminoma in the context of acute pulmonary embolism: a case report